American Society of Hirudotherapy

Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions

Research article published in American journal of perinatology (2018)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSagaram D et al. · American journal of perinatology, 2018

Abstract

INTRODUCTION: The rate of heparin-induced thrombocytopenia (HIT) on a population basis is unknown. The objective of this study was to characterize the risk for HIT during antepartum, delivery, and postpartum hospitalizations in the United States. MATERIALS AND METHODS: A large administrative database was used to determine the risk of HIT in hospitalized obstetric patients who received unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Patients were presumed to have HIT if they were exposed to UFH or LMWH, received a diagnosis of HIT, and were administered a medication for the treatment of HIT including bivalirudin, argatroban, fondaparinux, or lepirudin. We queried severe complications of HIT including arterial thrombosis, limb amputation, heart failure, and death. RESULTS: We identified 66,468 antepartum hospitalizations, 66,741 delivery hospitalizations, and 16,325 postpartum readmissions where women received pharmacologic prophylaxis. Of these, 10 antepartum admissions, 1 delivery admission, and 14 postpartum readmissions involved a diagnosis of HIT with treatment of bivalirudin, argatroban, fondaparinux, or lepirudin. There were no deaths and no diagnoses of arterial thrombosis, limb amputation, heart failure, and death. CONCLUSION: Risk for HIT among hospitalized obstetric patients is low. In this cohort, no cases of death or severe complications were noted in relation to the diagnosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsAdolescentAdultArginineDatabases, FactualDelivery, ObstetricFemaleFondaparinuxHeparinHeparin, Low-Molecular-WeightHirudinsHospitalizationHumansMiddle AgedPeptide FragmentsPipecolic AcidsPostpartum PeriodPregnancyRecombinant ProteinsRisk AssessmentSulfonamidesThrombocytopeniaUnited StatesYoung Adult

Summary

Analysis of a large US administrative database found heparin-induced thrombocytopenia risk is low among obstetric hospitalizations, with only 25 treated cases identified across antepartum, delivery and postpartum admissions and no deaths or severe complications observed.

Why This Matters for Hirudotherapy

This large database study characterized the risk of heparin-induced thrombocytopenia (HIT) among hospitalized obstetric patients, identifying 25 total cases across antepartum, delivery, and postpartum admissions among over 149,000 hospitalizations involving heparin prophylaxis. The study identified HIT cases based on diagnosis and administration of bivalirudin, argatroban, fondaparinux, or lepirudin, finding no associated deaths or severe complications. The abstract provides no information regarding the biological origins of these medications or any connection to leeches, hirudin, or hirudotherapy. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Sagaram D, Siddiq Z, Eisenberger AB, Ananth CV, Wright JD, D'Alton ME, et al. Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. Am J Perinatol. 2018;35(9):898-903. doi:10.1055/s-0038-1627096. PMID: 29421832

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.